Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations

Leukemia volume 23, pages 777–783 (2009)Cite this article

Abstract

Diffuse large B-cell lymphoma (DLBCL) having both t(14;18) and 8q24 translocations is rare. We evaluated the clinical characteristics and prognoses of patients with DLBCL carrying both t(14;18) and 8q24 translocations. A total of 1972 patients with non-Hodgkin's lymphoma were treated in the Adult Lymphoma Treatment Study Group (ALTSG) from 1998 to 2007. Nineteen cases of de novo DLBCL with the dual translocation were identified. The dual translocation was observed in 19 of 394 patients with DLBCL (10 males and 9 females, with a median age of 61 years). The dual translocation was observed significantly more frequently among patients with high lactate dehydrogenase levels, B symptoms, bone marrow involvement and advanced stage. Immunophenotyping was performed and showed DLBCL with a germinal center type in the majority of cases. Progression-free survival and overall survival rates were significantly lower in patients with the dual translocation than in those with other translocation. DLBCL patients with concurrent t(14;18) and 8q24 translocations have very poor prognosis. Even if patients had a complete response to chemotherapy, they subsequently suffered early relapse. In this study, only a few patients received rituximab, and its usefulness could not be assessed. Future studies with larger numbers of patients are required.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152–3162.

    CAS  PubMed  Google Scholar 

  2. Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006; 107: 4207–4213.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Boxer LM, Dang CV . Translocations involving c-myc and c-myc function. Oncogene 2001; 20: 5595–5610.

    Article  CAS  PubMed  Google Scholar 

  4. Ladanyi M, Offit K, Jhanwar SC, Filippa DA, Chaganti RS . MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas. Blood 1991; 77: 1057–1063.

    CAS  PubMed  Google Scholar 

  5. Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152–3162.

    CAS  PubMed  Google Scholar 

  6. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, Pickering DL et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99: 2285–2290.

    Article  CAS  PubMed  Google Scholar 

  7. Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 2007; 92: 1335–1342.

    Article  CAS  PubMed  Google Scholar 

  8. Kanungo A, Medeiros LJ, Abruzzo LV, Lin P . Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol 2006; 19: 25–33.

    Article  CAS  PubMed  Google Scholar 

  9. Niitsu N, Okamoto M, Aoki S, Okumura H, Tadashi Y, Miura I et al. Multicenter phase II study of the CyclOBEAP (CHOP-like+etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma. Ann Haematol 2006; 85: 374–380.

    Article  CAS  Google Scholar 

  10. Hashimoto K, Miura I, Chyubachi A, Saito M, Miura AB . Correlations of chromosome abnormalities with histologic and immunologic characteristics in 49 patients from Akita, Japan with non-Hodgkin lymphoma. Cancer Genet Cytogenet 1995; 81: 56–65.

    Article  CAS  PubMed  Google Scholar 

  11. Mitelman F . An International System for Human Cytogenetic Nomenclature. ISCN: S Karger, Basel, 1995.

    Google Scholar 

  12. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282.

    Article  CAS  PubMed  Google Scholar 

  13. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al., The International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586.

    Article  PubMed  Google Scholar 

  14. Shipp MA, International non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994.

    Article  Google Scholar 

  15. McClure RF, Remstein ED, Macon WR, Dewald GW, Habermann TM, Hoering A et al. Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol 2005; 29: 1652–1660.

    Article  PubMed  Google Scholar 

  16. Haralambieva E, Boerma EJ, van Imhoff GW, Rosati S, Schuuring E, Müller-Hermelink HK et al. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol 2005; 29: 1086–1094.

    PubMed  Google Scholar 

  17. McDonnell TJ, Korsmeyer SJ . Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 1991; 349: 254–256.

    Article  CAS  PubMed  Google Scholar 

  18. Nakamura N, Nakamine H, Tamaru J, Nakamura S, Yoshino T, Ohshima K et al. The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement. Mod Pathol 2002; 15: 771–776.

    Article  PubMed  Google Scholar 

  19. Frost M, Newell J, Lones MA, Tripp SR, Cairo MS, Perkins SL . Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol 2004; 121: 384–392.

    Article  PubMed  Google Scholar 

  20. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF et al. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419–2430.

    Article  CAS  PubMed  Google Scholar 

  21. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ et al. Lymphoma/Leukemia Molecular Profiling Project. Molecular Diagnosis of Burkitt's Lymphoma. N Engl J Med 2006; 354: 2431–2442.

    Article  CAS  PubMed  Google Scholar 

  22. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106: 1569–1580.

    Article  CAS  PubMed  Google Scholar 

  23. Mead GM, Sydes MR, Walewski J, Grigg A, Hatton CS, Pescosta N, et al., UKLG LY06 collaborators. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002; 13: 1264–1274.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan

    N Niitsu

  2. Adult Lymphoma Treatment Study Group (ALTSG), Nagoya, Japan

    N Niitsu, M Okamoto, I Miura & M Hirano

Authors
  1. N Niitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Hirano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N Niitsu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Niitsu, N., Okamoto, M., Miura, I. et al. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 23, 777–783 (2009). https://doi.org/10.1038/leu.2008.344

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.344

Keywords

This article is cited by

Search

Advanced search

Quick links